<b>Background/Objective:</b> Breast cancer (BC) management has traditionally relied on static clinicopathologic and immunohistochemical biomarkers (hormone receptor status, HER2 expression, and proliferative activity assessed at diagnosis). Here, NR4A1 is linked to breast carcinoma.